Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
GERN's Cash to Debt is ranked higher than
99% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 45.69 vs. GERN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
GERN' s Cash to Debt Range Over the Past 10 Years
Min: 0.87  Med: 8280.04 Max: No Debt
Current: No Debt
Equity to Asset 0.95
GERN's Equity to Asset is ranked higher than
94% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. GERN: 0.95 )
Ranked among companies with meaningful Equity to Asset only.
GERN' s Equity to Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.91 Max: 0.97
Current: 0.95
0.37
0.97
F-Score: 3
Z-Score: 18.05
M-Score: 17.70
WACC vs ROIC
24.56%
-123.54%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -485.19
GERN's Operating margin (%) is ranked lower than
70% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -88.05 vs. GERN: -485.19 )
Ranked among companies with meaningful Operating margin (%) only.
GERN' s Operating margin (%) Range Over the Past 10 Years
Min: -4069.18  Med: -2842.68 Max: -1.54
Current: -485.19
-4069.18
-1.54
Net-margin (%) -469.51
GERN's Net-margin (%) is ranked lower than
70% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.71 vs. GERN: -469.51 )
Ranked among companies with meaningful Net-margin (%) only.
GERN' s Net-margin (%) Range Over the Past 10 Years
Min: -4066.28  Med: -2767.01 Max: 0.13
Current: -469.51
-4066.28
0.13
ROE (%) -21.53
GERN's ROE (%) is ranked higher than
60% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -33.76 vs. GERN: -21.53 )
Ranked among companies with meaningful ROE (%) only.
GERN' s ROE (%) Range Over the Past 10 Years
Min: -60.98  Med: -39.36 Max: 0.03
Current: -21.53
-60.98
0.03
ROA (%) -20.51
GERN's ROA (%) is ranked higher than
58% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: -29.98 vs. GERN: -20.51 )
Ranked among companies with meaningful ROA (%) only.
GERN' s ROA (%) Range Over the Past 10 Years
Min: -53.81  Med: -35.38 Max: 0.03
Current: -20.51
-53.81
0.03
ROC (Joel Greenblatt) (%) -15286.60
GERN's ROC (Joel Greenblatt) (%) is ranked lower than
91% of the 916 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. GERN: -15286.60 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GERN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -26858.87  Med: -2542.17 Max: 70.53
Current: -15286.6
-26858.87
70.53
Revenue Growth (3Y)(%) 120.10
GERN's Revenue Growth (3Y)(%) is ranked higher than
95% of the 472 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. GERN: 120.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GERN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -81.5  Med: -26.3 Max: 192.4
Current: 120.1
-81.5
192.4
EPS Growth (3Y)(%) -100.00
GERN's EPS Growth (3Y)(%) is ranked lower than
99% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. GERN: -100.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GERN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -100  Med: -12.3 Max: 23.9
Current: -100
-100
23.9
GuruFocus has detected 4 Warning Signs with Geron Corp $GERN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GERN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

GERN Guru Trades in Q4 2015

Joel Greenblatt 299,986 sh (New)
First Eagle Investment 159,700 sh (-3.04%)
Paul Tudor Jones 14,543 sh (-7.82%)
» More
Q1 2016

GERN Guru Trades in Q1 2016

Jim Simons 453,480 sh (New)
Paul Tudor Jones 104,800 sh (+620.62%)
Joel Greenblatt 466,859 sh (+55.63%)
First Eagle Investment 159,700 sh (unchged)
» More
Q2 2016

GERN Guru Trades in Q2 2016

Jim Simons 461,580 sh (+1.79%)
First Eagle Investment 159,700 sh (unchged)
Paul Tudor Jones 88,300 sh (-15.74%)
Joel Greenblatt 33,232 sh (-92.88%)
» More
Q3 2016

GERN Guru Trades in Q3 2016

Paul Tudor Jones 169,600 sh (+92.07%)
Jim Simons 515,380 sh (+11.66%)
Joel Greenblatt Sold Out
First Eagle Investment 144,700 sh (-9.39%)
» More
» Details

Insider Trades

Latest Guru Trades with GERN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:SVA, NAS:CRBP, NAS:EDGE, OTCPK:PXRB, NAS:MNKD, NAS:PTGX, NAS:ARNA, NAS:XBIT, NAS:RARX, NAS:PRTK, NAS:NLNK, NAS:PTI, NAS:ADAP, NAS:VYGR, NAS:TRVN, NAS:AGEN, NAS:TLGT, NAS:MRUS, AMEX:BTX, NAS:CARA » details
Traded in other countries:GON.Germany,
Geron Corp is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic products for oncology such as telomerase inhibitor, imetelstat and in hematologic myeloid malignancies, among others.

Geron Corp was incorporated in the State of Delaware on November 28, 1990. It is a clinical stage biopharmaceutical company developing a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company operates in the segment of the discovery and development of therapeutic products for oncology. It owns commercial rights with U.S. patent coverage extending through 2025 for imetelstat. Its patent rights relating to telomerase cover the cloned genes that encode the RNA component and the catalytic protein component of human telomerase, cells that are immortalized by expression of recombinant hTERT, and cancer diagnostics based on detecting the expression of telomerase in cancer cells. The Company is subject to various and often changing federal, state, local and international laws, rules, regulations, guidelines and recommendations relating to safe working conditions and manufacturing practices.

Ratios

vs
industry
vs
history
P/B 2.38
GERN's P/B is ranked higher than
63% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 3.62 vs. GERN: 2.38 )
Ranked among companies with meaningful P/B only.
GERN' s P/B Range Over the Past 10 Years
Min: 1.07  Med: 2.67 Max: 12.12
Current: 2.38
1.07
12.12
P/S 49.51
GERN's P/S is ranked lower than
79% of the 682 Companies
in the Global Biotechnology industry.

( Industry Median: 10.89 vs. GERN: 49.51 )
Ranked among companies with meaningful P/S only.
GERN' s P/S Range Over the Past 10 Years
Min: 11.3  Med: 124.93 Max: 620
Current: 49.51
11.3
620
Current Ratio 15.72
GERN's Current Ratio is ranked higher than
88% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. GERN: 15.72 )
Ranked among companies with meaningful Current Ratio only.
GERN' s Current Ratio Range Over the Past 10 Years
Min: 3.44  Med: 11.41 Max: 33.57
Current: 15.72
3.44
33.57
Quick Ratio 15.72
GERN's Quick Ratio is ranked higher than
89% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. GERN: 15.72 )
Ranked among companies with meaningful Quick Ratio only.
GERN' s Quick Ratio Range Over the Past 10 Years
Min: 3.44  Med: 11.41 Max: 33.57
Current: 15.72
3.44
33.57
Days Sales Outstanding 313.69
GERN's Days Sales Outstanding is ranked lower than
96% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 62.07 vs. GERN: 313.69 )
Ranked among companies with meaningful Days Sales Outstanding only.
GERN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.1  Med: 150.84 Max: 313.69
Current: 313.69
12.1
313.69

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -6.80
GERN's 3-Year Average Share Buyback Ratio is ranked higher than
64% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.20 vs. GERN: -6.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GERN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -37.8  Med: -17.3 Max: -2.1
Current: -6.8
-37.8
-2.1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.13
GERN's Price/Net Cash is ranked higher than
74% of the 518 Companies
in the Global Biotechnology industry.

( Industry Median: 6.31 vs. GERN: 3.13 )
Ranked among companies with meaningful Price/Net Cash only.
GERN' s Price/Net Cash Range Over the Past 10 Years
Min: 1.45  Med: 3.92 Max: 223.42
Current: 3.13
1.45
223.42
Price/Net Current Asset Value 2.94
GERN's Price/Net Current Asset Value is ranked higher than
74% of the 634 Companies
in the Global Biotechnology industry.

( Industry Median: 5.82 vs. GERN: 2.94 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
GERN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.39  Med: 3.69 Max: 116.57
Current: 2.94
1.39
116.57
Price/Tangible Book 2.47
GERN's Price/Tangible Book is ranked higher than
70% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. GERN: 2.47 )
Ranked among companies with meaningful Price/Tangible Book only.
GERN' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.26  Med: 3.16 Max: 19.03
Current: 2.47
1.26
19.03
Price/Median PS Value 0.41
GERN's Price/Median PS Value is ranked higher than
84% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. GERN: 0.41 )
Ranked among companies with meaningful Price/Median PS Value only.
GERN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.05  Med: 0.66 Max: 7.2
Current: 0.41
0.05
7.2
Earnings Yield (Greenblatt) (%) -17.58
GERN's Earnings Yield (Greenblatt) (%) is ranked lower than
64% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. GERN: -17.58 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GERN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -18.14  Med: 0.3 Max: 0.4
Current: -17.58
-18.14
0.4

More Statistics

Revenue (TTM) (Mil) $6.29
EPS (TTM) $ -0.18
Beta2.96
Short Percentage of Float21.91%
52-Week Range $1.81 - 3.43
Shares Outstanding (Mil)159.15

Analyst Estimate

Dec16
Revenue (Mil $)
EPS ($) -0.25
EPS w/o NRI ($) -0.25
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for GERN

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: IBTX, INSM, GERN, INO, EQU Apr 07 2013 
WEEKLY CFO SELLS HIGHLIGHT: HTM, OVTI, VSEA, KSWS,GERN, ATRC Jun 20 2011 
Geron Corp. Reports Operating Results (10-Q) Oct 29 2010 
Geron: Buyer Beware Oct 13 2010 
Geron Corp. (GERN) President and CEO Thomas Okarma sells 18,874 Shares Jun 03 2010 
Geron Corp. (GERN) EVP and CFO David Greenwood sells 14,746 Shares Jun 03 2010 
Banking 60% on the Day the World Changed: FDA Approves Geron to Test Embryonic Stem Cells on Humans Jan 24 2009 
The Next Boom Emerges Nov 23 2008 

More From Other Websites
Geron Corp. breached its 50 day moving average in a Bearish Manner : GERN-US : January 12, 2017 Jan 12 2017
Biotech Industry Off to a Strong Start in 2017 Latest Reports on Halozyme Therapeutics and Geron Jan 09 2017
GERON CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Jan 09 2017
ETFs with exposure to Geron Corp. : December 29, 2016 Dec 29 2016
Geron Corp. breached its 50 day moving average in a Bullish Manner : GERN-US : December 26, 2016 Dec 26 2016
Geron Corp. – Value Analysis (NASDAQ:GERN) : December 19, 2016 Dec 19 2016
Geron Corp. breached its 50 day moving average in a Bullish Manner : GERN-US : December 16, 2016 Dec 16 2016
ETFs with exposure to Geron Corp. : December 12, 2016 Dec 12 2016
Geron Reports Imetelstat Presentations at American Society of Hematology Annual Meeting Dec 06 2016
ETFs with exposure to Geron Corp. : November 30, 2016 Nov 30 2016
Geron Corp. breached its 50 day moving average in a Bearish Manner : GERN-US : November 29, 2016 Nov 29 2016
GERON CORP Files SEC form 8-K, Other Events Nov 21 2016
Geron Corp. breached its 50 day moving average in a Bearish Manner : GERN-US : November 17, 2016 Nov 17 2016
GERON CORP Financials Nov 10 2016
ETF’s with exposure to Geron Corp. : November 10, 2016 Nov 10 2016
Geron Corp. :GERN-US: Earnings Analysis: Q3, 2016 By the Numbers : November 9, 2016 Nov 09 2016
Geron Announces November Investor Conference Presentation Webcasts Nov 07 2016
Geron Announces November Investor Conference Presentation Webcasts Nov 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)